Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase.

Mereniuk TR, El Gendy MA, Mendes-Pereira AM, Lord CJ, Ghosh S, Foley E, Ashworth A, Weinfeld M.

Mol Cancer Ther. 2013 Oct;12(10):2135-44. doi: 10.1158/1535-7163.MCT-12-1093. Epub 2013 Jul 24.

2.

NLK is a novel therapeutic target for PTEN deficient tumour cells.

Mendes-Pereira AM, Lord CJ, Ashworth A.

PLoS One. 2012;7(10):e47249. doi: 10.1371/journal.pone.0047249. Epub 2012 Oct 29.

3.

High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing.

Sims D, Mendes-Pereira AM, Frankum J, Burgess D, Cerone MA, Lombardelli C, Mitsopoulos C, Hakas J, Murugaesu N, Isacke CM, Fenwick K, Assiotis I, Kozarewa I, Zvelebil M, Ashworth A, Lord CJ.

Genome Biol. 2011 Oct 21;12(10):R104. doi: 10.1186/gb-2011-12-10-r104.

4.

Functional viability profiles of breast cancer.

Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, Bajrami I, Costa-Cabral S, Rafiq R, Ahmad AS, Cerone MA, Natrajan R, Sharpe R, Shiu KK, Wetterskog D, Dedes KJ, Lambros MB, Rawjee T, Linardopoulos S, Reis-Filho JS, Turner NC, Lord CJ, Ashworth A.

Cancer Discov. 2011 Aug;1(3):260-73. doi: 10.1158/2159-8290.CD-11-0107. Epub 2011 Aug 2.

5.

Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen.

Mendes-Pereira AM, Sims D, Dexter T, Fenwick K, Assiotis I, Kozarewa I, Mitsopoulos C, Hakas J, Zvelebil M, Lord CJ, Ashworth A.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2730-5. doi: 10.1073/pnas.1018872108. Epub 2011 Apr 11.

6.

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.

Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, Vatcheva R, Savage K, Mackay A, Lord CJ, Ashworth A, Reis-Filho JS.

Sci Transl Med. 2010 Oct 13;2(53):53ra75. doi: 10.1126/scitranslmed.3001538.

7.

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A.

EMBO Mol Med. 2009 Sep;1(6-7):315-22. doi: 10.1002/emmm.200900041.

Supplemental Content

Loading ...
Support Center